logo
Plus   Neg
Share
Email

Protalix: Phase III BRIDGE Switch-over Trial With PRX-102 Meets Main Objectives

Protalix BioTherapeutics, Inc. (PLX) reported positive topline results from its Phase III BRIDGE clinical trial of pegunigalsidase alfa, or PRX-102 for the treatment of Fabry Disease. The company said the topline results showed substantial improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate in both male and female patients who were switched from agalsidase alfa to PRX-102.

Einat Brill Almon, Protalix's Senior Vice President, Product Development, said: "We look forward to the continued findings from our other ongoing Phase III studies of PRX-102, with the final results from the BRIGHT study expected in the fourth quarter of 2020, and interim results from the BALANCE study expected in the first half of 2021."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT